Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

VViridian Therapeutics, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
V

Viridian Therapeutics, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
    Sep 2, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
    Aug 6, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
    Jun 26, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics to Participate in Upcoming June Investor Conferences
    May 27, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
    May 7, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
    May 5, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
    May 5, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
    May 5, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
    Mar 30, 2026Viridian Therapeutics, Inc. Press Releases
  • Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
    Feb 26, 2026Viridian Therapeutics, Inc. Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions